SHIRE PLC: Results of the 2014 Annual General Meeting

 Results of the 2014 Annual General Meeting  April 29, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that at its Annual General Meeting held at The Merrion Hotel, Upper Merrion Street, Dublin 2, Ireland at 1.30 pm today, all resolutions contained in the notice of meeting were decided by poll vote. The results of the poll are as follows:  Resolution                       For        %     Against     %     Votes     Withheld                                 (including                            cast as                             discretionary                           a % of                                votes)                              relevant                                                                     shares                                                                  in issue Ordinary Resolutions  1. To receive the Company's 400,965,756   98.95% 4,249,303  1.05%   68.80%   1,472,435 Annual Report and Accounts for the year ended December 31, 2013.  2. To approve the           391,218,791   96.97% 12,224,728 3.03%   68.50%   3,243,975 Directors' Remuneration Report.  3. To approve the           374,694,890   94.71% 20,926,142 5.29%   67.17%   11,066,462 Directors' Remuneration Policy.  4. To elect Dominic         404,467,447   99.82% 716,284    0.18%   68.80%   1,503,763 Blakemore as a Director.  5. To re-elect William      400,680,783   98.89% 4,510,166  1.11%   68.80%   1,496,545 Burns as a Director.  6. To re-elect Dr. Steven   404,565,517   99.84% 628,936    0.16%   68.80%   1,493,041 Gillis as a Director.  7. To re-elect Dr. David    404,559,335   99.84% 630,570    0.16%   68.80%   1,497,589 Ginsburg as a Director.  8. To re-elect David        398,241,506   98.74% 5,089,868  1.26%   68.48%   3,356,120 Kappler as a Director.  9. To re-elect Susan Kilsby 391,916,029   96.72% 13,277,757 3.28%   68.80%   1,493,708 as a Director.  10. To re-elect Anne Minto  400,967,152   99.45% 2,206,094  0.55%   68.45%   3,514,248 as a Director.  11. To re-elect Dr.         404,554,602   99.84% 632,552    0.16%   68.80%   1,500,340 Flemming Ornskov as a Director.  12. To elect David Stout as 403,130,381   99.49% 2,060,469  0.51%   68.80%   1,496,644 a Director.  13. To re-appoint Deloitte  401,119,071   98.99% 4,096,849  1.01%   68.80%   1,471,574 LLP as the Company's Auditor.  14. To authorize the Audit, 402,286,337   99.93% 284,166    0.07%   68.35%   4,116,991 Compliance & Risk Committee to determine the remuneration of the Auditor.  15. To approve the increase 404,516,894   99.86% 553,107    0.14%   68.78%   1,617,493 in the Company's borrowing powers.  16. To authorize the        373,096,915   92.54% 30,095,078 7.46%   68.46%   3,495,501 allotment of shares. Special Resolutions  17. To authorize the        397,955,909   98.47% 6,202,843  1.53%   68.62%   2,528,742 disapp99.95lication of pre-emption rights.  18. To authorize market     404,995,809   99.95% 195,629    0.05%   68.80%   1,496,056 purchases.  19. To approve the notice   342,512,195   84.53% 62,696,077 15.47%  68.80%   1,479,222 period for general meetings.  As at the record date, April 27, 2014, there were 588,965,802 ordinary shares in issue (excluding shares held in treasury). Shareholders are entitled to one vote per share. A vote "withheld" is not a vote in law and is not counted in the calculation of the proportion of votes validly cast.  In accordance with Listing Rule 9.6.2R copies of the relevant resolutions passed at the meeting have been submitted to the National Storage Mechanism and will be available for viewing shortly at: www.morningstar.co.uk/uk/nsm.  Tony Guthrie Deputy Company Secretary  For further information please contact:  Investor Relations Jeff Poulton                  jpoulton@shire.com   +1 781 482 0945 Eric Rojas                    erojas@shire.com     +1 781 482 0999 Sarah Elton-Farr              seltonfarr@shire.com +44 1256 894157  Media Jessica Mann                  jmann@shire.com      +44 1256 894 280  NOTES TO EDITORS  Shire enables people with life-altering conditions to lead better lives.  Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.  We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.  www.shire.com  END